(244) Healthcare costs associated with the care of patients with chronic inflammatory demyelinating polyneuropathy receiving immunoglobulin or neonatal fragment crystallizable receptor inhibitor therapies in the US

Background: : Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease characterized by peripheral neuropathy, and sensory and/or motor impairment. Maintenance therapies include intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), facilitated SCIG (fSCIG), and neonatal fragment crystallizable receptor inhibitor (anti-FcRn).

Objective: : To assess healthcare costs associated with the care of US patients with CIDP receiving maintenance therapy.

Methods: : This noninterventional, retrospective cohort study used the Komodo Health Research Database Plus (January 1, 2016 to March 31, 2025). Adults (aged ≥18 years at index [date of first treatment claim]), with ≥2 claims for CIDP diagnosis (ICD-10-CM G61.81) and continuous enrollment for ≥6 months pre- and ≥3 months post-index were included. Patients were stratified into cohorts based on CIDP treatment: IVIG, SCIG, fSCIG, or anti-FcRn. Demographics and disease characteristics were described for the baseline period (6 months pre-index); healthcare costs were evaluated from index to the earliest of death, end of enrollment or end of data availability. Costs are presented as median (Q1–Q3) in US Dollars per patient per month (PPPM).

Results: : A total of 4,098, 544, 12, and 59 patients, respectively, were represented in the IVIG, SCIG, fSCIG, and anti-FcRn cohorts, with median follow-up periods of 24.0, 24.5, 6.6, and 4.8 months. At baseline, median age ranged from 55.5 years (anti-FcRn) to 66.0 years (SCIG); typically, patients were male (50.0–71.2%) and white (58.3–81.4%). Total all-cause costs (presented as PPPM) were highest for anti-FcRn ($44,073 [26,544–72,594]) followed by fSCIG ($14,504 [8,488–17,839]), SCIG ($12,687 [7,293–20,267]), and IVIG ($8,857 [4,406–15,303]). Total CIDP-related costs were $43,214 (24,555–70,216) for anti-FcRn, $11,202 (5,941–15,903) for fSCIG, $11,187 (5,640–18,552) for SCIG, and $6,520 (2,529–12,611) for IVIG. Costs of treatments of interest were: $43,069 (23,081–68,961) for anti-FcRN, $10,352 (5,597–15,820) for fSCIG, $9,399 (4,332–16,684) for SCIG, and $4,586 (1,416–9,541) for IVIG. CIDP-related medical costs (excluding treatment-of-interest costs) were highest for IVIG ($685 [217–1,979]), followed by SCIG ($535 [202–1,420]), anti-FcRn ($323 [125–1,355]), and fSCIG ($177 [80–1,425]).

Conclusions: : CIDP is associated with high monthly healthcare costs, primarily driven by treatments of interest, particularly in the anti-FcRn cohort. CIDP-related medical costs, excluding treatment, were lowest in the fSCIG cohort.

Sponsorship:: Takeda Pharmaceuticals USA, Inc.